Rocket One Inc. (RKTO) Stock Price & Analysis
Rocket One Inc. (RKTO) rose 0.51% to USD 0.69 as of September 8, 2026 at 06:20 UTC, according to Nexqual real-time market data.
RKTO last closed at USD 0.69; the session ranged USD 0.68–0.71 on volume of 181,562 shares. Market capitalization is —, with a 52-week range of USD 0.49–2.45 (NCM). Source: Nexqual, September 8, 2026 at 06:20 UTC.
Key Statistics (as of September 8, 2026 at 06:20 UTC)
| Price | USD 0.69 |
|---|---|
| Change | ▲ 0.51% (up) |
| Previous Close | USD 0.69 |
| Open | USD 0.69 |
| Day Range | USD 0.68 – 0.71 |
| 52-Week Range | USD 0.49 – 2.45 |
| Volume | 181,562 shares |
| Market Cap | — |
| Exchange | NCM |
Technical Analysis (RKTO)
Nexqual's technical model rates RKTO "SELL" based on 2 bullish and 5 bearish signals across 128 daily candles, as of September 8, 2026 at 06:20 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 29.9 (oversold) |
| vs SMA50 | Below (USD 0.8) |
| MACD | -0.04 (negative) |
From Rocket One Inc.'s Latest SEC 10-K Filing (filed 2026-03-27)
Key Strengths & Strategy (as disclosed to the SEC)
- The BioLexa Platform is a proprietary, patented, drug compound platform for the treatment of eczema.
- In the U.S., the FDA regulates such products under the FDCA and the Public Health Services Act and implements related regulations.
- Our policy is to actively seek the broadest intellectual property protection possible for our products, proprietary information and proprietary technology through a combination of contractual arrangements and patents, both in the U.S. and elsewhere in the world.
- The license enables us to develop the platform for any indications in humans.
Partnerships
- Proceeding under this regulatory pathway, we will be able to rely upon publicly available data with respect to our active ingredient in our NDA submission to the FDA for marketing approval.   On June 7, 2021, we entered into a sponsored research agreement with Washington University in St.
- At this time, we do not anticipate conducting any further trials in Australia.   Preclinical Development   HT-004   On November 20, 2019, we entered into a license agreement with NC State pursuant to which NC State granted us an exclusive license to HT-004 for treating allergic diseases.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| PHIO | Phio Pharmaceuticals Corp. | USD 1.08 | ▼ 4.42% |
| ADTX | Aditxt, Inc. | USD 0.01 | ▲ 0% |
| ENSC | Ensysce Biosciences, Inc. | USD 0.46 | ▲ 2.93% |
| PALI | Palisade Bio, Inc. | USD 2.09 | ▲ 5.03% |
| ENVB | Enveric Biosciences, Inc. | USD 1.39 | ▼ 3.47% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 06:20 UTC. This page is informational and not investment advice.